Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + melphalan
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lenalidomide + melphalan is a combination regimen used primarily in the treatment of multiple myeloma and related plasma cell disorders. Lenalidomide is an immunomodulatory agent that acts by altering the substrate specificity of the Cereblon E3 ubiquitin ligase complex (CRL4^CRBN), leading to degradation of key transcription factors (IKZF1, IKZF3) essential for malignant plasma cell survival and stimulating immune responses via increased interleukin 2 and interferon gamma production[6]. Melphalan is an alkylating agent that cross-links DNA strands at the N7 position of guanine, disrupting DNA synthesis and transcription, resulting in cytotoxicity to both resting and dividing tumor cells[5][1]. The combination has been studied for use in multiple myeloma as well as AL amyloidosis[8].
- Brand names
- RevlimidAlkeranEvomela
- Other names
- lenalidomide + melphalan
02
Targets
CRBN (Cereblon)DNA
Beyond the preview
Go deeper on lenalidomide + melphalan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + melphalan.